Clinical Trial Update: Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating best corrected visual acuity in AMD patients treated with intravitreal aflibercept (VEGF Trap-Eye).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• VEGF Trap-Eye (aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Age - Related Macular Degeneration (AMD) | Phase 4 | Status: COMPLETED | Results posted: 2017-12-22